The current clinical trials should give us more information: Theyre comparing which works better and which is safer, and results are expected in December 2026
Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection
Both injectable and oral tirzepatide activate the same GLP-1 and GIP pathways and carry equivalent gallstone risk
Phase 3 data shows approximately 22-25% weight loss, making it competitive with retatrutide through a completely different mechanism
Whether you want to prevent early signs of aging, rejuvenate your skin, or enjoy a comprehensive facial enhancement plan, our warm and professional environment makes your journey enjoyable and rewarding